CCT128930 is primarily utilized in biochemical research as a selective inhibitor of protein kinase B (Akt). Its application is significant in studying cellular signaling pathways, particularly those involved in cell survival, proliferation, and metabolism. Researchers employ it to investigate the role of Akt in various diseases, including cancer, where aberrant Akt signaling is often observed. By inhibiting Akt, CCT128930 helps in understanding the mechanisms of tumor growth and resistance to therapies, aiding in the development of targeted cancer treatments. Additionally, it is used in preclinical studies to explore potential therapeutic strategies for other conditions linked to dysregulated Akt activity, such as diabetes and cardiovascular diseases.